OTIC Otonomy Inc.

2.59
+0.01  (+0%)
Previous Close 2.58
Open 2.57
Price To Book 1.15
Market Cap 79,475,217
Shares 30,685,412
Volume 852
Short Ratio
Av. Daily Volume 45,923

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 3Q 2019 with data due 2H 2020.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 trial initiation announced April 11, 2019 with data due 1H 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 1H 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
  2. Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT
  3. Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates
  4. Otonomy: 1Q Earnings Snapshot
  5. Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
  6. Otonomy, Inc. to Host Earnings Call
  7. Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
  8. Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
  9. Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
  10. Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
  11. Do Institutions Own Otonomy, Inc. (NASDAQ:OTIC) Shares?
  12. Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
  13. The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
  14. Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
  15. Will Otonomy Continue to Surge Higher?
  16. Edited Transcript of OTIC earnings conference call or presentation 4-Mar-19 9:30pm GMT
  17. Those Who Purchased Otonomy Shares Three Years Ago Have A 84% Loss To Show For It
  18. Otonomy to Participate in Two Upcoming Investor Conferences
  19. Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  20. Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update